Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: Francois Goelo who wrote (16921)	10/19/1999 10:04:00 AM
From: Stock Watcher	Read Replies (1) \| Respond to of 52051

watching PHMG & MRTO; sw

To: Francois Goelo who wrote (16921)	10/19/1999 11:12:00 AM
From: StockDung	Read Replies (1) \| Respond to of 52051

Anyone that would like a copy of SFLK's dismal audited financials please P.M. me with a fax number and I would be happy to fax you a copy.

To: Francois Goelo who wrote (16921)	10/19/1999 11:31:00 AM
From: Jeffrey L. Henken	Respond to of 52051

The latest buy recommendation on WASP. Sounds pretty good and the stock looks strong this morning: finance.yahoo.com otcbbstock.com Wasatch Pharmaceuticals - Aggressive Buy - Short term target $3.50 EVER HAD A ZIT? What if you had a bunch of them? How about one of these disfiguring skin conditions: cystic acne, acne, psoriasis, molluscum, eczema, contact dermatitus, folliculitus, seborrhea, cold sores, athletes foot, and other minor skin disorders. Ugly stuff isn't it? How would you like to invest in a company whose research proves it can not only help but actually cure these skin conditions in the majority of cases? Great right, but what would you say if I also told you that this company has a skin rejuvenation formula that major skin care companies are already making overtures to Wasatch to acquire? You might just want a piece of this company. Well you can own a piece of that company because it is currently listed on the OTC BB in the Healthcare Sector. WASP - OTC BB Float: 5.1 Million shares Outstanding: 17 Million shares Wasatch Pharmaceuticals has been in business since 1986. Until recently they have been largely a research and development company. Earlier this year in a series of press releases the company discussed the outstanding results of their research. As a result the stock ran to $2 1/2 per share. We believe the stock is now poised to make a move to even greater heights. Recent press releases have detailed the company's acquisition of initial funding and the targeting of that funding. This money is being put to good use. Investors can expect the company to make a number of milestone announcements soon. What kind of announcements? First off we expect the company's web site to be up shortly after this recommendation is published. On that web site investors will be able to find detailed information on the company's clinical trials and their astounding results. The results that are so spectacular that we expect the FDA to grant Wasatch FDA approval for OTC usage of their products without any additional clinical trials. In addition the current funding has allowed Wasatch to begin the necessary audits to once again become fully reporting. The stock has only got a float of little over 5 million shares. The sky is the limit for this stock in our opinion. How much money making potential does this company have? We are not just talking million dollar markets but actual billion dollar markets. The company currently is operating two clinics in Utah where it's products have been used to conduct exhaustive research. Those clinics could become very profitable, quite soon, as it is expected that insurance providers will accept the company's applications for third party coverage. Why would they do that? It's simple, a cure cost a heck of a lot less than constantly treating symptoms like current dermatological treatments do now. Wasatch plans to open over 300 clinics in the next few years. That could mean an astounding amount of revenue. In addition the potential for licensing these products is also astronomical. This company's research is so outstanding that as additional funding becomes available Wasatch will be bringing on board a management team that will really set the skin care world on fire. Once that happens then Wasatch will actually consider real negotiations with companies like Loreal, and others, which have already made overt offers. Investor Contact: Wasatch Pharmaceutical Inc., Midvale Gary Heesch, 801/272-1709 Disclaimer: Investing in OTC BB stocks can be extremely risky. The authors of this site are not connected with the financial industry and nothing here should be construed as giving financial advice. Prospective investors should contact a suitably qualified financial advisor. No warranty or guarantee is given regarding the accuracy, reliability, veracity, or completeness of the information provided here or by following links from this page, and under no circumstances will the author or service provider be liable for any loss including but not limited to direct, indirect, incidental, special or consequential damages caused by using the information, or as a result of the risks inherent in the stock market.